407 related articles for article (PubMed ID: 23475636)
1. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
Swain SM; Ewer MS; Cortés J; Amadori D; Miles D; Knott A; Clark E; Benyunes MC; Ross G; Baselga J
Oncologist; 2013; 18(3):257-64. PubMed ID: 23475636
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
[TBL] [Abstract][Full Text] [Related]
3. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J; Cortés J; Kim SB; Im SA; Hegg R; Im YH; Roman L; Pedrini JL; Pienkowski T; Knott A; Clark E; Benyunes MC; Ross G; Swain SM;
N Engl J Med; 2012 Jan; 366(2):109-19. PubMed ID: 22149875
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.
Cortés J; Baselga J; Im YH; Im SA; Pivot X; Ross G; Clark E; Knott A; Swain SM
Ann Oncol; 2013 Oct; 24(10):2630-2635. PubMed ID: 23868905
[TBL] [Abstract][Full Text] [Related]
6. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
Swain SM; Kim SB; Cortés J; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Knott A; Clark E; Ross G; Benyunes MC; Baselga J
Lancet Oncol; 2013 May; 14(6):461-71. PubMed ID: 23602601
[TBL] [Abstract][Full Text] [Related]
7. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
Swain SM; Baselga J; Miles D; Im YH; Quah C; Lee LF; Cortés J
Ann Oncol; 2014 Jun; 25(6):1116-21. PubMed ID: 24685829
[TBL] [Abstract][Full Text] [Related]
8. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
Xu B; Li W; Zhang Q; Li Q; Wang X; Li H; Sun T; Yin Y; Zheng H; Feng J; Zhu H; Siddiqui A; Macharia H; Knott A
Breast Cancer Res Treat; 2023 Feb; 197(3):503-513. PubMed ID: 36463547
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.
McCormack PL
Drugs; 2013 Sep; 73(13):1491-502. PubMed ID: 23982598
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Schneeweiss A; Chia S; Hickish T; Harvey V; Eniu A; Hegg R; Tausch C; Seo JH; Tsai YF; Ratnayake J; McNally V; Ross G; Cortés J
Ann Oncol; 2013 Sep; 24(9):2278-84. PubMed ID: 23704196
[TBL] [Abstract][Full Text] [Related]
11. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.
Xu B; Li W; Zhang Q; Shao Z; Li Q; Wang X; Li H; Sun T; Yin Y; Zheng H; Feng J; Zhang H; Lei G; Restuccia E
Breast Cancer Res Treat; 2020 Aug; 182(3):689-697. PubMed ID: 32564260
[TBL] [Abstract][Full Text] [Related]
12. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
[TBL] [Abstract][Full Text] [Related]
13. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).
Miles D; Baselga J; Amadori D; Sunpaweravong P; Semiglazov V; Knott A; Clark E; Ross G; Swain SM
Breast Cancer Res Treat; 2013 Nov; 142(1):89-99. PubMed ID: 24129974
[TBL] [Abstract][Full Text] [Related]
14. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Bondarenko I; Paluch-Shimon S; Wardley A; Merot JL; du Toit Y; Easton V; Lindegger N; Miles D;
Ann Oncol; 2019 May; 30(5):766-773. PubMed ID: 30796821
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.
Swain SM; Im YH; Im SA; Chan V; Miles D; Knott A; Clark E; Ross G; Baselga J
Oncologist; 2014 Jul; 19(7):693-701. PubMed ID: 24869931
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
17. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Kuemmel S; Tondini CA; Abraham J; Nowecki Z; Itrych B; Hitre E; Karaszewska B; Juárez-Ramiro A; Morales-Vásquez F; Pérez-García JM; Cardona-Huerta S; Monturus E; Sequi M; Restuccia E; Benyunes M; Martín M
Breast Cancer Res Treat; 2021 Jun; 187(2):467-476. PubMed ID: 33748921
[TBL] [Abstract][Full Text] [Related]
19. Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.
Fleeman N; Bagust A; Beale S; Dwan K; Dickson R; Proudlove C; Dundar Y
Pharmacoeconomics; 2015 Jan; 33(1):13-23. PubMed ID: 25138171
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
